Information Provided By:
Fly News Breaks for November 12, 2018
INFI
Nov 12, 2018 | 07:46 EDT
JPMorgan analyst Anupam Rama downgraded Infinity Pharmaceuticals to Underweight from Neutral without a price target. The data for IPI-549 needs to continue to mature, Rama tells investors in a research note. After the company presented initial data from the IPI-549 plus nivolumab combination portion of the MARIO-1 study this weekend, the analyst continues to believe Infinity is a "show me" story. He thinks the shares will be a relative underperformer of his coverage universe in the first half of 2019.
News For INFI From the Last 2 Days
There are no results for your query INFI